SCHEMBL6510137

SCHEMBL6510137

O=C(Nc1ccc2oc(C(=O)NO)cc2c1)c1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.60
KMT2A Q03164 6/20 0.60
NPC1 O15118 9/20 0.57
RAB9A P51151 9/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
HPGD P15428 1/20 0.57
TP53 P04637 4/20 0.57
PKM P14618 1/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
HDAC1 Q13547 2/20 0.55
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
NLRP3 Q96P20 1/20 0.52
ALPG P10696 1/20 0.51
PIN1 Q13526 1/20 0.51
PLAU P00749 1/20 0.50
MAPT P10636 1/20 0.50
KCNK3 O14649 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14260744 0.90 NPC1 (0.51) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6510072 0.88 RAB9A (0.51) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6506633 0.88 RAB9A (0.74) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6514424 0.83 ALDH1A1 (0.66) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6506287 0.82 MEN1 (0.70) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL11781581 0.80 PLAU (0.51) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL28891069 0.76 NPC1 (0.68) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL13485789 0.76 NPC1 (0.68) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6509267 0.75 BCAT1 (0.50) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL6506293 0.75 HDAC1 (0.58) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO claimed
US-20050137234-A1 Histone deacetylase inhibitors SYRRX, INC. 2005-06-23 US claimed
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO disclosed
WO-2005066151-A2 HISTONE DEACETYLASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2005-07-21 WO disclosed
US-20050137234-A1 Histone deacetylase inhibitors SYRRX, INC. 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137234-A1 Histone deacetylase inhibitors HDAC1, HDAC5, HDAC11 MEN1 2925/4885KMT2A 45/4885NPC1 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.